02699nam 2200397 450 991064749630332120230330232008.0(CKB)5680000000300312(NjHacI)995680000000300312(EXLCZ)99568000000030031220230330d2022 uy 0engur|||||||||||txtrdacontentcrdamediacrrdacarrierCOVID-19 drug development recent advances, new perspectives and applications /edited by Arli Aditya ParikesitLondon :IntechOpen,[2022]©20221 online resource (166 pages) illustrations1-80356-989-1 1-80356-990-5 Includes bibliographical references.1. Introductory Chapter: Current Perspective of COVID-19 Drugs 22 -- 2. Pluralism Medical Treatment, Prevention, and Control of COVID-19 Infection and Its Long-Sufferings among the Older Adults in the Northeast of Thailand from 2019 to 2022 142 -- 3. Baricitinib in the Treatment of COVID-19 53 -- 4. New Perspective and Applications of Homeopathy in Treating COVID-19 Symptoms 28 -- 5. Treatments for the Infection by SARS-CoV-2 49 -- 6. Inclusive Review on Existing Treatment and Management Modalities for COVID-19 39 -- 7. COVID-19: From Pathophysiology to Treatment 35 -- 8. COVID-19 Drug Development: Role of Drug Repurposing 16.COVID-19 is a rampant worldwide problem. It is caused by the SARS-CoV-2 virus and is manifest in different variants. The Delta variant compromised existing therapeutic and preventive options for this disease and is beginning to be replaced by the Omicron variant. Through pharmaceutical biotechnology, three different treatment approaches to COVID-19 have been developed: computer-aided drug design (CADD); rational drug design in the wet lab; and the advanced drug delivery system. These approaches are heavily influenced by advances in life sciences, such as the development of structural bioinformatics, the establishment of nanobiotechnology as a standard approach in drug design, and major advances in structural biology such as the development of the CryoEM method. This book will focus on providing possible solutions to the ongoing COVID-19 pandemic in light of these advances in life sciences.COVID-19 Drug Development COVID-19 (Disease)COVID-19 (Disease)614.59241Parikesit Arli AdityaNjHacINjHaclBOOK9910647496303321COVID-19 drug development3086007UNINA